According to the lawsuit, defendants throughout the Class Period provided investors with material information concerning deramiocel, Capricor’s lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (“BLA”) for deramiocel from the U.S. Food and Drug Administration (“FDA”). Further, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
